全部照片(1)

文件

Y0000489

霉酚酸酯

Name: 霉酚酸酯
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

同義詞:

(4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester, RS 61443, TM-MMF

登入查看組織和合約定價

全部照片(1)

About This Item

經驗公式（希爾表示法）:

C₂₃H₃₁NO₇

CAS號碼:

128794-94-5

分子量：:

433.49

MDL號碼:

MFCD00867568

分類程式碼代碼:

41116107

PubChem物質ID:

329830980

NACRES:

NA.24

推薦產品

Slide 1 of 10

1 of 10

Millipore

VT000096

Enterococcus faecalis WDCM 00009 Vitroids

Y0000519

吗替麦考酚酯

Supelco

PHR1451

霉酚酸酯

Millipore

VT001793

Escherichia coli WDCM 00179 Vitroids

Supelco

PHR3211

Mycophenolate Sodium

Sigma-Aldrich

SML0284

霉酚酸酯

Millipore

VT000092

Enterococcus faecalis WDCM 00009 Vitroids

Y0002200

Mycophenolate for system suitability

BP1254

霉酚酸酯

USP

1448956

霉酚酸酯

等級

pharmaceutical primary standard

API 家族

mycophenolate

製造商／商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN3CCOCC3

InChI

1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+

InChI 密鑰

RTGDFNSFWBGLEC-SYZQJQIISA-N

基因資訊

human ... IMPDH1(3614) , IMPDH2(3615)

尋找類似的產品？前往產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Mycophenolate mofetil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化／生理作用

Mycophenolate mofetil is a prodrug of mycophenolic acid (Cat. # M5255) that is cleaved by nonspecific esterases in vivo to produce the parent compound. Mycophenolic acid blocks inosine monophosphate dehydrogenase and is a potent immunosuppresive agent.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

訊號詞

Danger

危險聲明

H302,H360D,H372,H410

防範說明

P202 - P260 - P264 - P273 - P301 + P312 - P308 + P313

危險分類

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 1B - STOT RE 1

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 1

1 of 1

Supelco

50744

富马酸二甲酯

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

Eduardo F Mysler et al.

Arthritis and rheumatism, 65(9), 2368-2379 (2013-06-07)

To investigate the efficacy and safety of ocrelizumab in patients with class III/IV lupus nephritis (LN). Patients were randomized 1:1:1 to receive placebo, 400 mg ocrelizumab, or 1,000 mg ocrelizumab given as an intravenous infusion on days 1 and 15

Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin.

Christopher J Yates et al.

Transplantation, 96(8), 726-731 (2013-08-02)

The sensitivity of fasting plasma glucose (FPG) in screening for new-onset diabetes after transplantation (NODAT) has been questioned, particularly in the presence of moderate-dose prednisolone, where peak plasma glucose occurs 7 to 8 hr after administration. Oral glucose tolerance testing

Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.

P Satwani et al.

Leukemia, 29(2), 448-455 (2014-06-19)

The outcome of children, adolescents and young adults (CAYA) with poor-risk recurrent/refractory lymphoma is dismal (⩽30%). To overcome this poor prognosis, we designed an approach to maximize an allogeneic graft vs lymphoma effect in the setting of low disease burden.

Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial.

K Budde et al.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 14(12), 2796-2806 (2014-10-04)

This Phase III randomized trial examined efficacy and safety of a novel once-daily extended-release tacrolimus formulation (LCP-Tacro [LCPT]) versus twice-daily tacrolimus in de novo kidney transplantation. Primary efficacy end point was proportion of patients with treatment failure (death, graft failure

Outcomes of pancreas retransplantation after simultaneous kidney-pancreas transplantation are comparable to pancreas after kidney transplantation alone.

John Seal et al.

Transplantation, 99(3), 623-628 (2014-08-26)

There is a paucity of contemporary data describing the results of pancreas retransplantation (PRT). As a measure of utility, we wished to determine whether PRT could produce equivalent short-term and long-term recipient outcomes to primary pancreas after kidney (PAK) transplantation.

查看所有相關論文

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務

文件

霉酚酸酯

European Pharmacopoeia (EP) Reference Standard

About This Item

推薦產品

屬性

等級

API 家族

製造商／商標名

應用

格式

儲存溫度

SMILES 字串

InChI

InChI 密鑰

基因資訊

相關類別

描述

一般說明

應用

生化／生理作用

包裝

其他說明

相關產品

相關產品

安全資訊

象形圖

訊號詞

危險聲明

防範說明

危險分類

儲存類別代碼

水污染物質分類（WGK）

閃點（°F）

閃點（°C）

文件

分析證明 (COA)

已經擁有該產品？

客戶也查看了

同儕審查論文

技術服務